Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 9 ] It is also used to treat adults with heart failure and chronic kidney disease .
July 11, 2024 at 8:34 AM. By Michael Erman and Manas Mishra. (Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year ...
Sennacherib's Annals are the annals of the Assyrian king Sennacherib.They are found inscribed on a number of artifacts, and the final versions were found in three clay prisms inscribed with the same text: the Taylor Prism is in the British Museum, the Oriental Institute Prism in the Oriental Institute of Chicago, and the Jerusalem Prism is in the Israel Museum in Jerusalem.
SGLT2 inhibitor. SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney ), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption ...
August 12, 2024 at 7:22 AM. (Reuters) -Ascendis Pharma's said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder. Ascendis ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer. Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK ...
Canagliflozin is an anti-diabetic medication used to improve blood sugar control in people with type 2 diabetes. It is a third-line medication to metformin. [ 9] Per the British National Formulary it is also less preferred than a sulfonylurea as of 2019, while the American Diabetes Association and European Association for the Study of Diabetes ...
In each trial, HbA1c was measured from the start of the trial to the end of the trial and compared between the semaglutide group and the other groups. [ 25 ] The FDA also considered data from one separate trial (NCT #01720446) of 3297 participants with type 2 diabetes who were at high risk for cardiovascular events. [ 25 ]